Usefulness of the Trh Test in the Management of Patients with Differentiated Thyroid Cancer

1986 ◽  
Vol 72 (6) ◽  
pp. 597-600 ◽  
Author(s):  
Antonio Castagnoli ◽  
M. Teresa Rosaria De Cristofaro ◽  
Ivano Taddei ◽  
Silvana Forni ◽  
Cosimo Roberto Russo ◽  
...  

Thirty patients thyroidectomized for differentiated thyroid cancer were studied. Serum TSH was assayed in basal conditions and after TRH stimulation, while patients were in suppressive therapy with thyroid hormones. The basal TSH was normal in all the patients and less than 2 μ/ml in 20 patients. The TRH test was negative (no TSH response) in 27 patients and in all the cases with the basal TSH lower than 2 μU/ml.

Medicine ◽  
2020 ◽  
Vol 99 (28) ◽  
pp. e21190
Author(s):  
Chunhua Liu ◽  
Haihong Lv ◽  
Qian Li ◽  
Songbo Fu ◽  
Jiaojiao Tan ◽  
...  

1994 ◽  
Vol 19 (1) ◽  
pp. 49-53 ◽  
Author(s):  
A M SAMUEL ◽  
M N MEHTA ◽  
K B DESAI

2018 ◽  
Vol 65 (8) ◽  
pp. 474-476
Author(s):  
María Guadalupe Guijarro de Armas ◽  
Carmen Pérez Blanco ◽  
Pablo Carrasco Lara ◽  
María Merino Viveros ◽  
Isabel Pavón de Paz

2020 ◽  
Author(s):  
Thera P. Links ◽  
Trynke van der Boom ◽  
Wouter T. Zandee ◽  
Joop D Lefrandt

Thyroid hormone stimulates cardiac inotropy and chronotropy via direct genomic and non-genomic mechanisms. Hyperthyroidism magnifies these effects, resulting in an increase in heart rate, ejection fraction and blood volume. Hyperthyroidism also affects thrombogenesis and this may be linked to a probable tendency towards thrombosis in patients with hyperthyroidism. Patients with hyperthyroidism are therefore at higher risk for atrial fibrillation, heart failure and cardiovascular mortality. Similarly, TSH suppressive therapy for differentiated thyroid cancer is associated with increased cardiovascular risk. In this review, we present the latest insights on the cardiac effects of thyroid suppression therapy for the treatment of thyroid cancer. Finally, we will show new clinical data on how to implement this knowledge into the clinical practice of preventive medicine.


1989 ◽  
Vol 120 (5) ◽  
pp. 547-558 ◽  
Author(s):  
Line Baldet ◽  
Jean-Claude Manderscheid ◽  
Daniel Glinoer ◽  
Claude Jaffiol ◽  
Béatrice Coste-Seignovert ◽  
...  

Abstract. In order to know how thyroid nodules and differentiated thyroid cancers are investigated and treated in 1988, an international inquiry was performed by mean of a questionnaire based on a well-defined case report of a 35-year-old female with a solitary small thyroid nodule. Clinicians were asked to indicate their diagnostic and therapeutic approaches to the reported case and to some variations. Analysis of the 157 responses from thyroid experts showed that three in vitro tests (sensitive-TSH, free T4 and total T4) and three in vivo tests (99mTc or radioiodide scintiscan, fine needle aspiration and ultrasonography) were performed most frequently. In the case of a solid and cold nodule and in the absence of fine needle aspiration results, 19% of respondents advocated suppressive therapy and 81% surgery. In the same clinical case, but whom fine needle aspiration had been performed and cytology was benign, surgery was advocated by 24%, suppressive therapy by 48% and a regular follow-up without treatment by 28% of respondents. When surgery was performed and the diagnosis was a differentiated thyroid cancer, (near) total thyroidectomy was more frequently chosen than partial thyroidectomy in both papillary (60 and 40%, respectively, of respondents) and follicular (74 and 26%, respectively, of respondents) cancers; 80% of clinicians did not change their surgical technique in relation to histological type of the tumour. Total thyroidectomy was more often recommended in most of the clinical or anatomical variations compared with the basic case report. Pre- or postoperative hormonal therapy was initiated with L-T4 and TSH suppression was controlled by sensitive-TSH and thyroglobulin determinations. After total thyroidectomy, 131I was used with similar modalities for papillary and follicular cancers to ablate a thyroid remnant.


2003 ◽  
Vol 88 (1) ◽  
pp. 211-214 ◽  
Author(s):  
Bernadette Biondi ◽  
Emiliano A. Palmieri ◽  
Loredana Pagano ◽  
Michele Klain ◽  
Giovanna Scherillo ◽  
...  

Eleven patients who had undergone total thyroidectomy for differentiated thyroid cancer and who were on chronic TSH-suppressive therapy with levothyroxine (l-T4), underwent 24-h Holter electrocardiogram and Doppler-echocardiography before and after acute recombinant human TSH (rhTSH) administration for disease staging. The treatment, which was generally well tolerated, did not affect circulating thyroid hormones levels, nor did it have measurable effects on heart rate, rhythm, left ventricular morphology, or systo-diastolic function. Notably, arterial blood pressure tended to be slightly reduced after rhTSH administration, although in no instance did the patients become frankly symptomatic. Our data demonstrate that rhTSH does not alter cardiovascular function acutely. Consequently, it can safely be used in the routine staging of patients affected by differentiated thyroid cancer.


Author(s):  
B. É. C. A. Sousa ◽  
B. C. Silva ◽  
T. de Oliveira Guidotti ◽  
M. C. Pires ◽  
M. M. S. Soares ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hosu Kim ◽  
Jaehoon Jung ◽  
Young-Seok Cho ◽  
Joon Young Choi ◽  
Hyunju Park ◽  
...  

AbstractSerum thyrotropin (TSH) level after thyroid surgery affects the prognosis of differentiated thyroid cancer (DTC). However, the effects of preoperative serum TSH levels on the prognosis of DTC remain contradictory. In this study, to better understand the relationship between preoperative TSH levels and the prognosis of DTC, we performed pattern analysis of prognostic factors of DTC according to preoperative serum TSH levels. We retrospectively reviewed the clinical records of patients who were diagnosed and treated for DTC at the Samsung Medical Center, between 1994 and 2016. We reviewed preoperative serum TSH levels and performed a pattern analysis with prognostic risk factors for DTC. For pattern analysis, TSH was divided into 10 groups of equal fractions (TSH decile). We found a linear association between preoperative TSH levels and extra-thyroidal extension and lymph node metastasis. However, primary tumor size and initial distant metastasis showed a bimodal peak, which was similar to the pattern of overall and disease-specific death. We found that preoperative TSH range which showed the lowest mortality rate was about 0.8 to 1.59 mIU/L, which are slightly lower normal TSH levels. Although there was no linear trend, the primary tumor size, initial distant metastasis, and mortality of DTC were closely related with preoperative TSH decile and they showed a bimodal pattern. The results obtained in this study provide additional information for understanding the association between preoperative TSH levels and DTC prognosis.


Sign in / Sign up

Export Citation Format

Share Document